{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:13:33Z","timestamp":1760908413322},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,9,12]],"date-time":"2007-09-12T00:00:00Z","timestamp":1189555200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s00280-007-0572-y","type":"journal-article","created":{"date-parts":[[2007,9,11]],"date-time":"2007-09-11T05:53:48Z","timestamp":1189490028000},"page":"51-58","source":"Crossref","is-referenced-by-count":11,"title":["In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines"],"prefix":"10.1007","volume":"62","author":[{"given":"Judith A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith K.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jubilee","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lois M.","family":"Ramondetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clinton F.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,9,12]]},"reference":[{"issue":"4\u20136","key":"572_CR1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000086967","volume":"68","author":"M Salzberg","year":"2005","unstructured":"Salzberg M, Thurlimann B, Bonnefois H, Fink D, Rochlitz C, von Moos R, Senn H (2005) Current concepts of treatment in advanced or recurrent ovarian cancer. Oncology 68(4\u20136):293\u2013298","journal-title":"Oncology"},{"issue":"2","key":"572_CR2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1517\/14728214.10.2.413","volume":"10","author":"LR Kelland","year":"2005","unstructured":"Kelland LR (2005) Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs 10(2):413\u2013424","journal-title":"Expert Opin Emerg Drugs"},{"key":"572_CR3","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/1097-0142(19901015)60:8+<2075::AID-CNCR2820601521>3.0.CO;2-F","volume":"60","author":"A Fojo","year":"1987","unstructured":"Fojo A, Thomas C, Robert C et al (1987) Multi-drug resistance in ovarian cancer. Cancer 60:2075\u20132080","journal-title":"Cancer"},{"issue":"suppl 4","key":"572_CR4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.7-suppl_4-2","volume":"7","author":"J Baselga","year":"2002","unstructured":"Baselga J (2002) Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 7(suppl 4):2\u20138","journal-title":"Oncologist"},{"issue":"1","key":"572_CR5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2003.09.030","volume":"92","author":"NG Cloven","year":"2004","unstructured":"Cloven NG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP (2004) In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol 92(1):160\u2013166","journal-title":"Gynecol Oncol"},{"key":"572_CR6","first-page":"247","volume":"107","author":"NJ Maihle","year":"2002","unstructured":"Maihle NJ, Baron AT, Barrette BA et al (2002) EGF\/ErbB receptor family in ovarian cancer. Cancer Treat Res 107:247\u2013258","journal-title":"Cancer Treat Res"},{"key":"572_CR7","first-page":"3355","volume":"48","author":"PJK Kuppen","year":"1988","unstructured":"Kuppen PJK, Schuitemaker H, van\u2019t Veer LJ, deBruijn EA, van Ossteron AT, Schrier PI (1988) cis-Diaminedichloroplatinum (II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res 48:3355\u20133359","journal-title":"Cancer Res"},{"key":"572_CR8","doi-asserted-by":"crossref","first-page":"13137","DOI":"10.1016\/S0021-9258(19)38277-8","volume":"265","author":"K Kawai","year":"1990","unstructured":"Kawai K, Kamatani N, Georges E, Ling V (1990) Identification of a membrane glycoprotein over expressed in murine lymphoma sub lines resistant to cis-diaminedichloroplatinum (II). J Biol Chem 265:13137\u20134212","journal-title":"J Biol Chem"},{"issue":"5","key":"572_CR9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/87912","volume":"7","author":"T Synold","year":"2001","unstructured":"Synold T, Dussalt I, Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7(5):584\u2013590","journal-title":"Nat Med"},{"key":"572_CR10","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ygyno.2003.09.037","volume":"92","author":"JA Smith","year":"2004","unstructured":"Smith JA, Brown J, Martin MC, Ramondetta LM, Wolf JK (2004) An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecol Oncol 92:314\u2013319","journal-title":"Gynecol Oncol"},{"key":"572_CR11","first-page":"37a","volume":"21","author":"KS Albain","year":"2002","unstructured":"Albain KS et al (2002) Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21:37a","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl","key":"572_CR12","first-page":"A83","volume":"9","author":"DB Solit","year":"2003","unstructured":"Solit DB et al (2003) Pulsatile administration of the EGF receptor inhibitor gefitinib (\u2018Iressa\u2019 ZD 1839) is significantly more effective than continuous dosing sensitizing tumors to Taxol. Clin Cancer Res 9(Suppl):A83","journal-title":"Clin Cancer Res"},{"key":"572_CR13","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nrc1506","volume":"4","author":"RS Herbst","year":"2004","unstructured":"Herbst RS, Fukuora M, Baselga J (2004) Gefitinib\u2014a novel targeted approach to treating cancer. Nat Rev 4:956\u2013965","journal-title":"Nat Rev"},{"key":"572_CR14","first-page":"2053","volume":"6","author":"F Ciardiello","year":"2000","unstructured":"Ciardiello F, Caputo R, Bianco R et al (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053\u20132063","journal-title":"Clin Cancer Res"},{"key":"572_CR15","unstructured":"Finn RS, Beryt M, Pergram MD et al (2002) ZD 1839 (\u2018Iressa\u2019) acts synergistically with chemotherapy in ovarian cells expressing high levels of the EGFR. Proc Am Soc Clin Oncol 21:29b (A 1928)"},{"key":"572_CR16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ijc.10173","volume":"98","author":"I Naruse","year":"2002","unstructured":"Naruse I, Ohmori T, Ao Y, Fukumoto H, Kuroki T, Mori M, Saijo N (2002) Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 98:310\u2013315","journal-title":"Int J Cancer"},{"key":"572_CR17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1200\/JCO.2004.12.903","volume":"22","author":"J Baselga","year":"2004","unstructured":"Baselga J (2004) Combining the anti-EGFR agent gefitinib with chemotherapy in non-small cell lung cancer: how do we go from INTACT to impact? J Clin Oncol 22:759\u2013761","journal-title":"J Clin Oncol"},{"key":"572_CR18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1749-6632.2002.tb04101.x","volume":"963","author":"RI Nicholson","year":"2002","unstructured":"Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM (2002) Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptro-positive breast cancer. Ann NY Acad Sci 963:104\u2013115","journal-title":"Ann NY Acad Sci"},{"issue":"10","key":"572_CR19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/00001813-200511000-00009","volume":"16","author":"AH Braun","year":"2005","unstructured":"Braun AH, Stark K, Dirsch O, Hilger RA, Seeber S, Vanhoefer U (2005) The epidermal growth factor tryosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. Anticancer Drugs 16(10):1099\u20131108","journal-title":"Anticancer Drugs"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0572-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-007-0572-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0572-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T06:43:17Z","timestamp":1629700997000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-007-0572-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["572"],"URL":"https:\/\/doi.org\/10.1007\/s00280-007-0572-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,9,12]]}}}